vs
Ispire Technology Inc.（ISPR）与ARS Pharmaceuticals, Inc.（SPRY）财务数据对比。点击上方公司名可切换其他公司
ARS Pharmaceuticals, Inc.的季度营收约是Ispire Technology Inc.的1.4倍（$28.1M vs $20.3M），Ispire Technology Inc.净利率更高（-32.5% vs -147.1%，领先114.6%），Ispire Technology Inc.同比增速更快（-51.5% vs -67.6%）
Ispire科技是一家专注于先进雾化硬件及配套耗材研发、生产与销售的全球化科技企业，主要服务尼古丁及合法大麻消费市场，下设硬件、品牌大麻产品两大核心业务板块，覆盖北美、欧洲、亚太等核心市场，为B端合作商及终端用户提供合规创新的雾化解决方案。
ARS Pharmaceuticals是一家处于后期研发阶段的生物制药企业，专注于开发和商业化严重过敏反应创新疗法，核心产品为无需注射的肾上腺素鼻腔递送制剂，主要面向北美市场，服务存在致命过敏风险的成人及儿童患者群体。
ISPR vs SPRY — 直观对比
营收规模更大
SPRY
是对方的1.4倍
$20.3M
营收增速更快
ISPR
高出16.1%
-67.6%
净利率更高
ISPR
高出114.6%
-147.1%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $20.3M | $28.1M |
| 净利润 | $-6.6M | $-41.3M |
| 毛利率 | 17.1% | — |
| 营业利润率 | -33.9% | -147.6% |
| 净利率 | -32.5% | -147.1% |
| 营收同比 | -51.5% | -67.6% |
| 净利润同比 | 17.4% | -182.8% |
| 每股收益（稀释后） | $-0.12 | $-0.41 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ISPRSPRY
| Q4 25 | $20.3M | $28.1M | ||
| Q3 25 | $30.4M | $32.5M | ||
| Q2 25 | $20.1M | $15.7M | ||
| Q1 25 | $26.2M | $8.0M | ||
| Q4 24 | $41.8M | $86.6M | ||
| Q3 24 | $39.3M | $2.1M | ||
| Q2 24 | $37.3M | $500.0K | ||
| Q1 24 | $30.0M | $0 |
净利润ISPRSPRY
| Q4 25 | $-6.6M | $-41.3M | ||
| Q3 25 | $-3.3M | $-51.2M | ||
| Q2 25 | $-14.8M | $-44.9M | ||
| Q1 25 | $-10.9M | $-33.9M | ||
| Q4 24 | $-8.0M | $49.9M | ||
| Q3 24 | $-5.6M | $-19.1M | ||
| Q2 24 | $-3.5M | $-12.5M | ||
| Q1 24 | $-5.9M | $-10.3M |
毛利率ISPRSPRY
| Q4 25 | 17.1% | — | ||
| Q3 25 | 17.0% | — | ||
| Q2 25 | 12.3% | — | ||
| Q1 25 | 18.2% | — | ||
| Q4 24 | 18.5% | — | ||
| Q3 24 | 19.5% | — | ||
| Q2 24 | 28.3% | — | ||
| Q1 24 | 20.4% | — |
营业利润率ISPRSPRY
| Q4 25 | -33.9% | -147.6% | ||
| Q3 25 | -8.9% | -163.7% | ||
| Q2 25 | -72.7% | -302.9% | ||
| Q1 25 | -40.4% | -466.3% | ||
| Q4 24 | -17.6% | 54.5% | ||
| Q3 24 | -13.4% | -1051.6% | ||
| Q2 24 | -9.2% | -3068.0% | ||
| Q1 24 | -18.8% | — |
净利率ISPRSPRY
| Q4 25 | -32.5% | -147.1% | ||
| Q3 25 | -10.7% | -157.4% | ||
| Q2 25 | -73.4% | -285.6% | ||
| Q1 25 | -41.5% | -425.7% | ||
| Q4 24 | -19.1% | 57.7% | ||
| Q3 24 | -14.2% | -925.0% | ||
| Q2 24 | -9.4% | -2503.2% | ||
| Q1 24 | -19.7% | — |
每股收益（稀释后）ISPRSPRY
| Q4 25 | $-0.12 | $-0.41 | ||
| Q3 25 | $-0.06 | $-0.52 | ||
| Q2 25 | $-0.26 | $-0.46 | ||
| Q1 25 | $-0.19 | $-0.35 | ||
| Q4 24 | $-0.14 | $0.52 | ||
| Q3 24 | $-0.10 | $-0.20 | ||
| Q2 24 | $-0.07 | $-0.13 | ||
| Q1 24 | $-0.11 | $-0.11 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $17.6M | $245.0M |
| 总债务越低越好 | — | $96.4M |
| 股东权益账面价值 | $-7.7M | $114.3M |
| 总资产 | $84.4M | $327.7M |
| 负债/权益比越低杠杆越低 | — | 0.84× |
8季度趋势，按日历期对齐
现金及短期投资ISPRSPRY
| Q4 25 | $17.6M | $245.0M | ||
| Q3 25 | $22.7M | $288.2M | ||
| Q2 25 | $24.4M | $240.1M | ||
| Q1 25 | $23.5M | $275.7M | ||
| Q4 24 | $34.4M | $314.0M | ||
| Q3 24 | $37.7M | $204.6M | ||
| Q2 24 | $35.1M | $218.7M | ||
| Q1 24 | $39.5M | $223.6M |
总债务ISPRSPRY
| Q4 25 | — | $96.4M | ||
| Q3 25 | — | $96.2M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ISPRSPRY
| Q4 25 | $-7.7M | $114.3M | ||
| Q3 25 | $-1.8M | $147.7M | ||
| Q2 25 | $604.7K | $192.3M | ||
| Q1 25 | $14.8M | $229.0M | ||
| Q4 24 | $24.2M | $256.8M | ||
| Q3 24 | $30.7M | $201.0M | ||
| Q2 24 | $34.5M | $215.2M | ||
| Q1 24 | $35.9M | $223.9M |
总资产ISPRSPRY
| Q4 25 | $84.4M | $327.7M | ||
| Q3 25 | $96.4M | $372.8M | ||
| Q2 25 | $102.2M | $313.5M | ||
| Q1 25 | $115.7M | $327.3M | ||
| Q4 24 | $132.0M | $351.2M | ||
| Q3 24 | $129.0M | $217.6M | ||
| Q2 24 | $122.6M | $222.0M | ||
| Q1 24 | $108.0M | $227.6M |
负债/权益比ISPRSPRY
| Q4 25 | — | 0.84× | ||
| Q3 25 | — | 0.65× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.0M | $-43.5M |
| 自由现金流经营现金流 - 资本支出 | $-4.0M | — |
| 自由现金流率自由现金流/营收 | -19.9% | — |
| 资本支出强度资本支出/营收 | 0.3% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-14.2M | — |
8季度趋势，按日历期对齐
经营现金流ISPRSPRY
| Q4 25 | $-4.0M | $-43.5M | ||
| Q3 25 | $-1.2M | $-47.0M | ||
| Q2 25 | $4.7M | $-39.6M | ||
| Q1 25 | $-12.5M | $-40.7M | ||
| Q4 24 | $-3.2M | $42.0M | ||
| Q3 24 | $3.6M | $-14.5M | ||
| Q2 24 | $-1.4M | $-7.3M | ||
| Q1 24 | $3.4M | $-6.7M |
自由现金流ISPRSPRY
| Q4 25 | $-4.0M | — | ||
| Q3 25 | $-1.2M | $-47.2M | ||
| Q2 25 | $3.7M | $-39.6M | ||
| Q1 25 | $-12.7M | $-40.8M | ||
| Q4 24 | $-3.2M | $41.7M | ||
| Q3 24 | $3.3M | $-14.6M | ||
| Q2 24 | $-2.2M | $-7.3M | ||
| Q1 24 | $3.3M | $-6.8M |
自由现金流率ISPRSPRY
| Q4 25 | -19.9% | — | ||
| Q3 25 | -3.9% | -145.4% | ||
| Q2 25 | 18.6% | -252.2% | ||
| Q1 25 | -48.4% | -512.1% | ||
| Q4 24 | -7.7% | 48.2% | ||
| Q3 24 | 8.5% | -706.3% | ||
| Q2 24 | -5.9% | -1463.4% | ||
| Q1 24 | 10.9% | — |
资本支出强度ISPRSPRY
| Q4 25 | 0.3% | 0.0% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 4.8% | 0.3% | ||
| Q1 25 | 0.7% | 1.1% | ||
| Q4 24 | 0.1% | 0.3% | ||
| Q3 24 | 0.7% | 6.8% | ||
| Q2 24 | 2.0% | 7.6% | ||
| Q1 24 | 0.3% | — |
现金转化率ISPRSPRY
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.84× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ISPR
暂无分部数据
SPRY
| Products | $20.3M | 72% |
| Other | $7.8M | 28% |
